MCID: MYC005
MIFTS: 46

Myocardial Stunning

Categories: Cardiovascular diseases

Aliases & Classifications for Myocardial Stunning

MalaCards integrated aliases for Myocardial Stunning:

Name: Myocardial Stunning 12 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9767
MeSH 43 D017682
UMLS 71 C0206146

Summaries for Myocardial Stunning

MalaCards based summary : Myocardial Stunning is related to atrial standstill 1 and ventricular fibrillation, paroxysmal familial, 1, and has symptoms including polydipsia, fatigue and edema. An important gene associated with Myocardial Stunning is SLC9A1 (Solute Carrier Family 9 Member A1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Oxytocin signaling pathway. The drugs Heparin and Nicorandil have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and neutrophil, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 74 In cardiology, stunned myocardium is a state when some section of the myocardium (corresponding to area... more...

Related Diseases for Myocardial Stunning

Diseases related to Myocardial Stunning via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 atrial standstill 1 30.7 TNNT2 TNNI3 ACE
2 ventricular fibrillation, paroxysmal familial, 1 30.6 TNNT2 SLC9A1 KNG1 KCNJ5
3 intermediate coronary syndrome 30.4 TNNT2 TNNI3 SERPINC1 ACE
4 mitral valve insufficiency 30.3 TNNT2 TNNI3 ACE
5 cardiac arrest 30.2 TNNT2 SLC9A1 KNG1 ACE
6 hypertrophic cardiomyopathy 30.1 TNNT2 TNNI3 EDN1 ACE
7 pulmonary edema 29.8 TNNT2 TNNI3 SERPINC1 EDN1 AGTR1 ACE
8 acute myocardial infarction 29.7 TNNT2 TNNI3 SERPINC1 EDN1 AGTR1 ACE
9 coronary artery vasospasm 29.7 TNNI3 KNG1 EDN1 AHSP ACE
10 respiratory failure 29.7 SOD1 EDN1 CAT ACE
11 arteries, anomalies of 29.4 TNNT2 TNNI3 KNG1 EDN1 AGTR1 ACE
12 end stage renal failure 29.4 SOD1 CAT AGTR2 AGTR1 ACE
13 chronic kidney disease 29.3 TNNT2 TNNI3 SOD1 EDN1 AGTR1 ACE
14 kidney disease 29.1 TNNT2 EDN1 CAT AGTR2 AGTR1 ACE
15 coronary artery anomaly 28.8 TNNT2 TNNI3 SERPINC1 KNG1 KCNJ5 EDN1
16 stroke, ischemic 28.5 SERPINC1 AGTR2 AGTR1 ADORA3 ADORA1 ACE
17 congestive heart failure 28.4 TNNT2 TNNI3 KNG1 EDN1 AGTR1 ADORA1
18 ischemia 28.3 SOD1 SLC9A1 KNG1 KCNJ5 EDN1 CAT
19 cardiovascular system disease 28.2 SOD3 SOD1 SERPINC1 KNG1 EDN1 CAT
20 myocardial infarction 27.7 TNNT2 TNNI3 SOD3 SERPINC1 KNG1 KCNJ5
21 heart disease 27.3 TNNT2 TNNI3 SOD3 SERPINC1 KNG1 KCNJ5
22 meningitis and encephalitis 10.5 SOD1 CAT
23 coronary stenosis 10.5
24 familial isolated restrictive cardiomyopathy 10.5 TNNT2 TNNI3
25 rheumatic myocarditis 10.5 TNNT2 TNNI3
26 platelet aggregation, spontaneous 10.5 SOD1 SERPINC1
27 cardiogenic shock 10.5
28 meningococcal infection 10.4 SOD1 AGTR1
29 broken heart syndrome 10.4
30 anoxia 10.4 SOD1 KCNJ5
31 hyperlipoproteinemia, type iii 10.3
32 malignant renovascular hypertension 10.3 EDN1 AGTR1
33 malignant hypertensive renal disease 10.3 EDN1 AGTR1
34 endocarditis 10.3 TNNI3 SERPINC1 CAT
35 plantar fascial fibromatosis 10.3 AGTR2 AGTR1
36 toxic myocarditis 10.3 TNNI3 KNG1
37 hydrops, lactic acidosis, and sideroblastic anemia 10.2
38 volkmann contracture 10.2
39 retinal ischemia 10.1 SOD1 KNG1 CAT
40 alzheimer disease 5 10.1 AGTR1 ACE
41 familial vesicoureteral reflux 10.1 AGTR2 ACE
42 familial hyperaldosteronism 10.1 KCNJ5 AGTR1
43 cholesterol embolism 10.1 SERPINC1 ACE
44 striatal degeneration, autosomal dominant 2 10.1
45 myocarditis 10.1
46 idiopathic edema 10.1 EDN1 ACE
47 silent myocardial infarction 10.1 TNNT2 TNNI3 ACE
48 iga nephropathy 1 10.1 AGTR1 ACE
49 left bundle branch hemiblock 10.1 TNNT2 TNNI3 ACE
50 pericardium disease 10.1 TNNT2 TNNI3 ACE

Graphical network of the top 20 diseases related to Myocardial Stunning:



Diseases related to Myocardial Stunning

Symptoms & Phenotypes for Myocardial Stunning

UMLS symptoms related to Myocardial Stunning:


polydipsia, fatigue, edema, cyanosis, chills, asthenia, signs and symptoms, signs and symptoms, digestive, hot flushes, signs and symptoms, respiratory, oral manifestations, eye manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, skin manifestations, renal colic, mobility limitation, prodromal symptoms, medically unexplained symptoms

GenomeRNAi Phenotypes related to Myocardial Stunning according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.17 ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
2 Decreased substrate adherent cell growth GR00193-A-3 9.17 ADORA1 ADORA2B

MGI Mouse Phenotypes related to Myocardial Stunning:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
2 cardiovascular system MP:0005385 10.13 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
3 homeostasis/metabolism MP:0005376 10.13 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2
4 mortality/aging MP:0010768 10 ACE ADORA1 ADORA2B AGTR1 AGTR2 CAT
5 nervous system MP:0003631 9.7 ADORA1 ADORA2B AGTR1 AGTR2 EDN1 OPRD1
6 renal/urinary system MP:0005367 9.23 ACE ADORA1 ADORA2B ADORA3 AGTR1 AGTR2

Drugs & Therapeutics for Myocardial Stunning

Drugs for Myocardial Stunning (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
2
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
3 Nutmeg Approved Phase 4
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Ticagrelor Approved Phase 4 274693-27-5 9871419
7
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
8
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
9
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
10
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
11
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
12
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
15
Simendan Investigational Phase 4 131741-08-7
16
Cobalamin Experimental Phase 4 13408-78-1 6857388
17 calcium heparin Phase 4
18 Hormones Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Chlorhexidine gluconate Phase 4
21 Mace Phase 4
22 Calcium, Dietary Phase 4
23 Rosuvastatin Calcium Phase 4 147098-20-2
24 Anti-Arrhythmia Agents Phase 4
25 Fibrinolytic Agents Phase 4
26 Anticholesteremic Agents Phase 4
27 Platelet Aggregation Inhibitors Phase 4
28 Analgesics, Non-Narcotic Phase 4
29 Hypolipidemic Agents Phase 4
30 Anti-Inflammatory Agents, Non-Steroidal Phase 4
31 Adrenergic Antagonists Phase 4
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Antipyretics Phase 4
34 Adrenergic beta-Antagonists Phase 4
35 Adrenergic beta-1 Receptor Antagonists Phase 4
36 Cyclooxygenase Inhibitors Phase 4
37 Antirheumatic Agents Phase 4
38 calcium channel blockers Phase 4
39 Analgesics Phase 4
40 Purinergic P2Y Receptor Antagonists Phase 4
41 Antimetabolites Phase 4
42 Lipid Regulating Agents Phase 4
43 Sympatholytics Phase 4
44 Sodium Channel Blockers Phase 4
45 Diuretics, Potassium Sparing Phase 4
46 Pharmaceutical Solutions Phase 4
47 Micronutrients Phase 4
48 Vitamins Phase 4
49 Trace Elements Phase 4
50 Vitamin B 12 Phase 4

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
2 Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure. Completed NCT00324766 Phase 4 levosimendan;placebo,
3 The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy) Completed NCT02767401 Phase 4 aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc
4 Prophylactic Administration of Levosimendan in Patients With Impaired Left Ventricular Function Undergoing Coronary Surgery Completed NCT01318460 Phase 4 Levosimendan infusion;Placebo infusion
5 The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease Enrolling by invitation NCT03372785 Phase 4 aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor
6 Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial Not yet recruiting NCT02687269 Phase 4 Ranolazine;Placebo
7 Intracoronary Administration of Levosimendan in Cardiac Surgery Patients Terminated NCT01500785 Phase 4 levosimendan;Vitamin B 12
8 Improving Outcomes in Patients Receiving Continuous Renal Replacement Therapy for Acute Kidney Injury by Cooling Blood in the Dialysis Circuit (CRRiTiCool): a Randomized Controlled Trial Not yet recruiting NCT04103307 Phase 2
9 Serial Echocardiography After Subarachnoid Hemorrhage (S.E.A.S.) Unknown status NCT00123695
10 Chinese People's Liberation Army General Hospital Unknown status NCT02930265 Liraglutide
11 Neurological Outcomes After Cardiac Arrest in Pulseless Electrical Activity in Comparison to Asystole. Are All Non-shockable Rhythms the Same? Unknown status NCT02033720
12 Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration Completed NCT02545426
13 Prediction of Left Ventricular Function Changes Using Low Dose Dobutamine Gated SPECT in Patients Referred for Viability Assessment: The DOGS (DObutamine Gated Spect)Study. Completed NCT00213746
14 The Efficiency and Safety of a High Energy Shock Protocol (360-360-360 J) Versus a Standard Escalating Energy Shock Protocol (125-150-200 J) in Cardioverting Atrial Fibrillation Completed NCT02923414
15 A Safety and Feasibility Study of Transcoronary Myocardial Buffering and Cooling During Primary Coronary Angioplasty to Reduce Myocardial Reperfusion Injury in Acute Myocardial Infarction. Completed NCT02312336
16 Evaluation of the Effects of Cooler Dialysate on Liver Perfusion, Endotoxemia and Uremic Toxin Handling in Hemodialysis Patients Completed NCT02997774
17 Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome Completed NCT00586183
18 Post-Stress Left Ventricular Contractile Dysfunction: Does It Represent Persistent Myocardial Ischemia or Stunning? Completed NCT00001528
19 Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology Completed NCT01179802
20 Utility of Serum Procalcitonin Levels to Distinguish Systemic Inflammatory Response From Systemic Infection in Febrile Subarachnoid Hemorrhage Patients Completed NCT00954551
21 Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients (ERSD) Recruiting NCT03539861
22 Randomized Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients Recruiting NCT02145260 Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate);Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
23 Cardiomyocyte Injury Following Acute Ischemic Stroke Recruiting NCT03892226
24 Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device Recruiting NCT03661229
25 Selective Intracoronary Hypothermia in Patients With ST-elevation Myocardial Infarction to Reduce Infarct Size Recruiting NCT03447834
26 Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients Active, not recruiting NCT02207153
27 Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation. Not yet recruiting NCT02770183
28 Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy Terminated NCT01048125 The Modified Oxford Technique for Baroreflex Sensitivity
29 Reduction of the Cardiac Proapoptotic Stress Response by Dexamethasone in Patients Undergoing Coronary Artery Bypass Grafting Surgery Withdrawn NCT00807521 Dexamethasone;Placebo

Search NIH Clinical Center for Myocardial Stunning

Cochrane evidence based reviews: myocardial stunning

Genetic Tests for Myocardial Stunning

Anatomical Context for Myocardial Stunning

MalaCards organs/tissues related to Myocardial Stunning:

40
Heart, Kidney, Neutrophil, Liver, Skin, Endothelial, Eye

Publications for Myocardial Stunning

Articles related to Myocardial Stunning:

(show top 50) (show all 1272)
# Title Authors PMID Year
1
Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters. 54 61
12831348 2003
2
Pharmacological evidence for persistent activation of ATP-sensitive potassium channels in the early phase of reperfusion and its protective role against myocardial stunning. 54 61
8901700 1996
3
Do ATP-sensitive potassium channels play a role in myocardial stunning? 54 61
8534242 1995
4
ATP-sensitive potassium channels and myocardial preconditioning. 54 61
7646421 1995
5
Suppression of Superoxide-Hydrogen Peroxide Production at Site IQ of Mitochondrial Complex I Attenuates Myocardial Stunning and Improves Postcardiac Arrest Outcomes. 61
31939812 2020
6
Chemical chaperones improve the functional recovery of stunned myocardium by attenuating the endoplasmic reticulum stress. 61
31385408 2020
7
Anesthesia Management for a Patient Undergoing Pulmonary Endarterctomy without Cardiopulmonary Bypass. 61
31793258 2020
8
Suppression of Superoxide-Hydrogen Peroxide Production at Site IQ of Mitochondrial Complex I Attenuates Myocardial Stunning and Improves Postcardiac Arrest Outcomes. 61
31725436 2019
9
Intradialytic exercise preconditioning: an exploratory study on the effect on myocardial stunning. 61
30590580 2019
10
Will Mary Jane Leave You Heartbroken? Marijuana Use and Risk of Takotsubo Cardiomyopathy. 61
31807375 2019
11
Paradoxical effect of testosterone supplementation therapy on cardiac ischemia/reperfusion injury in aged rats. 61
30930218 2019
12
Tyrosine nitration of mitochondrial proteins during myocardial ischemia and reperfusion. 61
31115776 2019
13
Myocardial stunning by gated SPECT: An old tool reinvented in a stunning turn. 61
29139036 2019
14
Additional value of systolic wall thickening in myocardial stunning evaluated by stress-rest gated perfusion SPECT. 61
29119373 2019
15
Renal Perfusion during Hemodialysis: Intradialytic Blood Flow Decline and Effects of Dialysate Cooling. 61
31053638 2019
16
Three-vessel myocardial bridging: A possible cause of myocardial stunning. 61
30031629 2019
17
Regional disparity in outcomes among patients hospitalized for Takotsubo cardiomyopathy in the United States✰. 61
30446395 2019
18
Perioperative ischaemic reperfusion injury and allograft function in the early post-transplantation period. 61
30919896 2019
19
High Dialysate Calcium Concentration is Associated with Worsening Left Ventricular Function. 61
30787343 2019
20
A rare case of transient left ventricular apical ballooning syndrome following living donor liver transplantation: A case report and literature review. 61
30771626 2019
21
Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI. 61
31692431 2019
22
Association of Central Venous Oxygen Saturation Variability and Mortality in Hemodialysis Patients. 61
30522104 2019
23
Tight coronary artery stenosis and takotsubo syndrome triggered each other: Well-illustrated in a case. 61
29804797 2018
24
Left ventricular dyssynchrony and abnormalities in wall motion, assessed by gated-SPECT as ischemic auxiliary markers. 61
30515745 2018
25
Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. 61
30413254 2018
26
Funny Lumps, Flaming Pheo, and a Broken Heart: A Rare Case of Pheochromocytoma. 61
30723645 2018
27
Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome: Results From the RETAKO Registry. 61
30316938 2018
28
Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review. 61
30309474 2018
29
Myocardial reperfusion injury and oxidative stress: Therapeutic opportunities. 61
30344955 2018
30
A Case of Takotsubo Cardiomyopathy After Local Anesthetic and Epinephrine Infiltration. 61
30357060 2018
31
The clinical usefulness of phase analysis in detecting coronary artery disease using dipyridamole thallium-201-gated myocardial perfusion imaging with a cadmium-zinc-telluride camera. 61
30171522 2018
32
Non-occlusive mesenteric ischaemia in out of hospital cardiac arrest survivors. 61
28045326 2018
33
Myocardial stunning-induced left ventricular dyssynchrony on gated single-photon emission computed tomography myocardial perfusion imaging. 61
29794947 2018
34
Myocardial Stunning After Electrocution With Complete Reversibility Within 24 Hours: Role of Repeat Transthoracic Echocardiograms in Potential Cardiac Transplant Donors. 61
30116458 2018
35
Percutaneous perfusion monitoring for the detection of hemodialysis induced cardiovascular injury. 61
29360287 2018
36
Takotsubo syndrome or myocardial stunning due to spasm of a non-obstructive left anterior descending coronary artery? 61
29923102 2018
37
Better characterization of dipyridamole-induced myocardial stunning by systolic wall thickening. A gated perfusion SPECT study. 61
29951894 2018
38
Extracorporeal Cardiopulmonary Resuscitation in Children of Asia Pacific: A Retrospective Analysis of Extracorporeal Life Support Organization Registry. 61
29893360 2018
39
Cardiovascular Abnormalities in Carbon Monoxide Poisoning. 61
24518173 2018
40
Editorial commentary: Interpreting and dealing with myocardial stunning. 61
29221767 2018
41
Current interpretation of myocardial stunning. 61
29221768 2018
42
Percutaneous biventricular Impella support in therapy-refractory cardiogenic shock. 61
29628145 2018
43
The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD. 61
29592914 2018
44
Prediction of functional recovery after primary PCI using the estimate of myocardial salvage in gated SPECT early after acute myocardial infarction. 61
29196789 2018
45
Takotsubo Syndrome: Clinical Features, Pathogenesis, Treatment, and Relationship with Cerebrovascular Diseases. 61
29569186 2018
46
Correlation between endothelial dysfunction and myocardial damage in acute phase of Tako-Tsubo cardiomyopathy: brachial flow mediated dilation as a potential marker for assessment of patient with Tako-Tsubo. 61
29027587 2018
47
Connexins and Nitric Oxide Inside and Outside Mitochondria: Significance for Cardiac Protection and Adaptation. 61
29867537 2018
48
Abnormal coronary vasoreactivity in transient left ventricular apical ballooning (tako-tsubo) syndrome. 61
29169759 2018
49
[New thoughts in mechanism research of acupuncture for myocardial stunning from κ-opioid receptor signaling pathway]. 61
29354941 2018
50
Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study. 61
30619056 2018

Variations for Myocardial Stunning

Expression for Myocardial Stunning

Search GEO for disease gene expression data for Myocardial Stunning.

Pathways for Myocardial Stunning

Pathways related to Myocardial Stunning according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 OPRD1 KNG1 EDN1 AGTR2 AGTR1 ADORA3
2
Show member pathways
12.28 KCNJ5 EDN1 AGTR1 ADORA2B
3 12.11 TNNI3 SLC9A1 EDN1 ADORA1
4
Show member pathways
12.03 TNNT2 TNNI3 EDN1 ACE
5
Show member pathways
11.78 TNNT2 TNNI3 SLC9A1 OPRD1 KNG1 AGTR2
6
Show member pathways
11.77 SOD1 ADORA3 ADORA2B ADORA1
7 11.7 OPRD1 KNG1 ADORA3 ADORA1
8 11.61 TNNT2 TNNI3 SLC9A1
9
Show member pathways
11.36 KNG1 AGTR2 AGTR1 ACE
10
Show member pathways
11.35 SOD3 SOD1 CAT
11
Show member pathways
11.21 ADORA3 ADORA2B ADORA1
12 11.1 EDN1 AGTR1 ADORA1 ACE
13 10.92 SOD3 SOD1 CAT

GO Terms for Myocardial Stunning

Cellular components related to Myocardial Stunning according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 SLC9A1 OPRD1 AGTR2 AGTR1 ADORA3 ADORA2B
2 cell GO:0005623 9.87 TNNI3 SOD1 SLC9A1 KNG1 EDN1 AGTR2
3 plasma membrane GO:0005886 9.47 SOD1 SLC9A3R2 SLC9A1 SERPINC1 OPRD1 KNG1
4 troponin complex GO:0005861 9.26 TNNT2 TNNI3
5 cardiac myofibril GO:0097512 9.16 TNNT2 TNNI3
6 cardiac Troponin complex GO:1990584 8.96 TNNT2 TNNI3

Biological processes related to Myocardial Stunning according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.03 OPRD1 KNG1 EDN1 AGTR2 AGTR1 ADORA3
2 negative regulation of apoptotic process GO:0043066 10 SOD1 SLC9A1 SIX4 CAT ADORA1
3 inflammatory response GO:0006954 9.93 KNG1 AGTR2 AGTR1 ADORA3 ADORA1
4 response to hypoxia GO:0001666 9.81 SOD3 EDN1 CAT ADORA1
5 cellular response to oxidative stress GO:0034599 9.79 SOD3 SOD1 CAT
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.72 OPRD1 EDN1 ADORA1
7 regulation of muscle contraction GO:0006937 9.65 TNNT2 TNNI3
8 cellular sodium ion homeostasis GO:0006883 9.65 SLC9A1 AGTR2
9 response to copper ion GO:0046688 9.64 SOD3 SOD1
10 superoxide anion generation GO:0042554 9.64 SOD1 EDN1
11 response to muscle stretch GO:0035994 9.63 SLC9A1 EDN1
12 negative regulation of blood coagulation GO:0030195 9.63 KNG1 EDN1
13 positive regulation of renal sodium excretion GO:0035815 9.62 EDN1 AGTR2
14 response to reactive oxygen species GO:0000302 9.62 SOD1 CAT
15 removal of superoxide radicals GO:0019430 9.6 SOD3 SOD1
16 negative regulation of ATPase activity GO:0032780 9.59 TNNT2 TNNI3
17 negative regulation of hormone secretion GO:0046888 9.58 EDN1 ADORA1
18 positive regulation of systemic arterial blood pressure GO:0003084 9.58 ADORA1 ACE
19 regulation of vasoconstriction GO:0019229 9.58 EDN1 AGTR1 ACE
20 angiotensin-activated signaling pathway GO:0038166 9.57 AGTR2 AGTR1
21 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.56 TNNI3 SLC9A1
22 regulation of blood pressure GO:0008217 9.56 SOD1 EDN1 AGTR2 ACE
23 regulation of blood vessel diameter GO:0097746 9.54 AGTR2 AGTR1 ACE
24 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.52 AGTR1 ACE
25 heart contraction GO:0060047 9.5 TNNI3 SOD1 ACE
26 hemoglobin metabolic process GO:0020027 9.49 CAT AHSP
27 response to ozone GO:0010193 9.48 EDN1 CAT
28 renin-angiotensin regulation of aldosterone production GO:0002018 9.46 AGTR2 AGTR1
29 relaxation of vascular smooth muscle GO:0060087 9.33 SOD1 ADORA2B ADORA1
30 adenosine receptor signaling pathway GO:0001973 9.13 ADORA3 ADORA2B ADORA1
31 regulation of sensory perception of pain GO:0051930 8.92 SLC9A1 OPRD1 EDN1 ADORA1

Molecular functions related to Myocardial Stunning according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 OPRD1 AGTR2 AGTR1 ADORA3 ADORA2B ADORA1
2 protein phosphatase 2B binding GO:0030346 9.4 SOD1 SLC9A1
3 superoxide dismutase activity GO:0004784 9.37 SOD3 SOD1
4 antioxidant activity GO:0016209 9.33 SOD3 SOD1 CAT
5 angiotensin type II receptor activity GO:0004945 9.32 AGTR2 AGTR1
6 troponin C binding GO:0030172 9.26 TNNT2 TNNI3
7 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
8 G protein-coupled adenosine receptor activity GO:0001609 8.8 ADORA3 ADORA2B ADORA1

Sources for Myocardial Stunning

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....